From: Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm
HIF-1α inhibitors | Target | Mechanism of inhibition | Pharmacological use |
---|---|---|---|
Aminoflavone, EZN-2698 | HIF-1α mRNA | HIF-1α mRNA expression | Therapeutic agents for breast cancer and advanced renal cell carcinoma (RCC) |
Topotecan, EZN-2208, SN38, Irinotecan | Topoisomerase I | HIF-1α translation | They are used to treat cancer of the ovaries and lymphoma |
Temsirolimus, Everolimus, Sirolimus | mTOR | They are used in breast cancer metastatic renal cell carcinoma treatment | |
LY294002, Wortmannin | PI3K | They are used to inhibit the solid tumors progression including breast cancer | |
Digoxin, Ouabain Proscillaridin | HIF-1α protein | Therapeutic agents for congestive heart failure | |
2ME2, ENDM-1198, ENMD-1200, ENMD-1237 | Microtubules (disruption) | Antimetastatic agents | |
Radicicol, KF58333 SCH66336, Apigenin Hsp90 GA, 17-AAG, 17AG, 17-DMAG | Hsp90 | HIF-1α stabilization | Anti-inflammatory and anti-cancer agents |
LW6 | HDAC/VHL | Treatment and prevention of cancer | |
Acriflavin | PAS-B | HIF-1α dimerization | Antiseptic & Anti-Bacterial agent |
Echinomycin | 5ˊ-CGTG-3ˊ | HIF-1/DNA binding | Antibiotic agent |
Doxorubicin, Danuorubicin | HRE | Anticancer agents | |
Chetomin | CH1domain of p300 | HIF-1 transcriptional activity | Antimicrobial agents with enhancing radiotherapy effect |
Bortezomib | C-TAD of HIF-1α and Asn803 of FIH | Anti-cancer agent for the treatment of relapsed and refractory multiple myeloma | |
YC −1, PX-478 | HIF-1protein/FIH | HIF-1α at multiple levels | Anti-cancer agents |